98%
921
2 minutes
20
Hair loss is a complex multifactorial process. The mechanisms by which caffeine and adenosine act against hair loss have been extensively researched, but little is known about their effects on the microbiome and lipidome of the scalp. Hair loss may be associated with the status of scalp microbiota and lipids. Further investigation is warranted to determine whether caffeine and adenosine can regulate scalp microbiota and lipids and thus help to prevent hair loss. The objective of this study was to assess the effect of shampoo containing caffeine and adenosine on the scalp microbiome and lipidome in subjects experiencing hair loss who were aged between 18 and 60 years. The study was a randomized, single-blind and parallel comparison trial involving full scalp treatment, which was conducted among 30 subjects experiencing hair loss. Samples were collected from subjects at baseline and at 12 weeks (±3 days). Microbiomes were analysed via 16S rDNA and ITS1 sequencing. Lipidome analysis was carried out using ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). At 12 weeks, significant clinical characteristics indicating an anti-hair loss effect were evident. Abundances of Pseudomonas, Escherichia-Shigella and Malassezia all decreased in the experimental group, whereas those of Talaromyces and Cutibacterium increased. In addition, levels of triglyceride (TG), diglyceride (DG), ceramide (Cer) and ceramide-1-phosphate (CerP) were all significantly impacted in the experimental group. Furthermore, abundances of lipid metabolites were tightly correlated with those of Escherichia-Shigella and Talaromyces. Caffeine and adenosine may enhance the anti-hair loss process through their effects on the lipidome and microbiome of the scalp.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ics.13072 | DOI Listing |
J Med Chem
September 2025
School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, PR China.
The prevalence of AGA is continuously rising, with an earlier age of onset. Currently, only minoxidil and finasteride have received FDA approval for the treatment of AGA, inadequately addressing the pressing clinical needs. Recently, the involvement of the Wnt/β-catenin signaling pathway in AGA has attracted increased research interest.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: Persistent chemotherapy-induced alopecia (pCIA) is a distressing side effect of antineoplastic agents, imposing significant psychological burdens on cancer survivors. Despite its impact, there are no standardized guidelines for diagnosis, prevention or management.
Objective: To establish consensus-based definitions, diagnostic criteria, grading systems and management recommendations for pCIA.
Cureus
August 2025
Department of Pharmacology, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidhyapeetham, Kochi, IND.
Introduction: Taxanes, including paclitaxel, docetaxel, and cabazitaxel, are widely used anticancer agents that disrupt cell division by binding to microtubules, but are associated with significant adverse reactions, particularly infusion-related reactions (IRRs), such as flushing, urticaria, and respiratory symptoms. Despite premedication with steroids, antihistamines, and antiemetics per guidelines, taxane-induced side effects remain prevalent and can result in treatment delays or discontinuation, impacting patient outcomes. This study aimed to observe and document the incidence and spectrum of adverse reactions to taxanes among premedicated cancer patients to improve management and overall chemotherapy success.
View Article and Find Full Text PDFClin Cosmet Investig Dermatol
September 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Rep
Purpose: Alopecia areata (AA) is a common, immune-mediated, non-scarring form of hair loss. Janus kinase inhibitors provide considerable insight into the treatment of severe AA. However, the efficacy and safety of upadacitinib treatment of adolescents and pediatric patients with severe AA is unclear, especially in those without concomitant atopic diseases.
View Article and Find Full Text PDFJ Assoc Res Otolaryngol
September 2025
Biological Sciences Platform, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Room M1 102, Toronto, ON, M4N 3M5, Canada.
Purpose: Delivery of therapeutics to the inner ear is complicated by their inaccessible location and the presence of the blood-labyrinth barrier that restricts most blood-borne compounds from entering the inner ear. This study addresses the challenge of optimal delivery in treating inner ear disease, focusing on magnetic targeting gene therapy using adeno-associated virus (AAV).
Methods: The investigation explores three AAV serotypes (AAV2 Quad Mut, AAV2 pANC80L65, and AAV9 PHP.